Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
KMO encodes a mitochondrion outer membrane protein that catalyzes the hydroxylation of L-tryptophan metabolite, L-kynurenine, to form L-3-hydroxykynurenine. Additionally we are shipping KMO Proteins (20) and KMO Kits (12) and many more products for this protein.
Showing 10 out of 53 products:
Human Polyclonal KMO Primary Antibody for FACS, IHC (p) - ABIN652604
Ligam, Manuelpillai, Wallace, Walker: Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. in Placenta 2005
Mouse (Murine) Polyclonal KMO Primary Antibody for ELISA, ICC - ABIN4329494
Vamos, Pardutz, Klivenyi, Toldi, Vecsei: The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. in Journal of the neurological sciences 2009
Mice lacking the enzyme kynurenine-3-monoxygenase (KMO) also showed no changes in hippocampal expression of several of these proteins or the 70-kDa and 100-kDa variants of Disrupted in Schizophrenia-1 (DISC1 (show DISC1 Antibodies)).
KMO KO mice have a robust biochemical phenotype that protects against extrapancreatic tissue injury to the lung, kidney and liver in experimental acute pancreatitis-multiple organ dysfunction syndrome.
KMO knockout mice have alterations in the levels of several tryptophan metabolites.
expression of KMO by Th17 cells serves to limit their continuous exposure to physiological levels of endogenous aryl hydrocarbon receptor (show AHR Antibodies) ligands in vivo.
partial protection against cerebral malaria was observed in C57BL/6 mice treated with Ro 61-8048, an inhibitor of kynurenine-3-hydroxylase. Protection was associated with suppressed levels of picolinic acid within the brain.
A comprehensive review of the molecular properties of KMO, including its kinetics, reaction mechanism, and inhibitor structure-activity relationship (SAR (show SARDH Antibodies)), is not currently available and, thus, is our focus here
SiRNA knockdown of the pathway components Kynurenine 3-monooxygenase and quinolinate phosphoribosyl transferase caused cells to revert to a state of susceptibility to 3HK-mediated apoptosis.
These results suggest that KMO exhibits tumor-promoting effects towards hepatocellular carcinoma (HCC (show FAM126A Antibodies)) and it may serve as a novel prognostic marker in HCC (show FAM126A Antibodies).
Results suggest that KMO variation influences a range of cognitive domains known to predict functional outcome in schizophrenia
Two KMO SNPs were observed more often in schizophrenia patient group compared with healthy controls.
findings from five independent cohorts suggest that genetic variation in KMO influences the risk for psychotic features in mania of bipolar disorder patients.
Study reporting on the first successful bacterial (Escherichia coli) expression of active FLAGtrade mark-tagged human KMO enzyme expressed in the soluble fraction and progress towards its purification.
analyzed association between KMO gene polymorphisms and CSF (show CSF2 Antibodies) concentrations of kynurenic acid in patients with schizophrenia and controls. results suggest that the nonsynonymous KMO SNP rs1053230 influences CSF (show CSF2 Antibodies) concentrations of KYNA.
the function KMO AND indoleamine 2,3-dioxygenase may change from a role in immunosuppression at the maternal-fetal interface in early pregnancy, to one associated with regulation of fetoplacental blood flow or placental metabolism in late gestation
Results suggest that kynurenine 3-monooxygenase is unlikely to be related to the development of schizophrenia in Japanese.
The carboxyl-terminal region of pig liver L-kynurenine 3-monooxygenase plays a dual role as a mitochondrial-targeting signal and an enzyme.
This gene encodes a mitochondrion outer membrane protein that catalyzes the hydroxylation of L-tryptophan metabolite, L-kynurenine, to form L-3-hydroxykynurenine. Studies in yeast identified this gene as a therapeutic target for Huntington disease.
, kynurenine 3-monooxygenase
, L-kynurenine 3-monooxygenase Fpk